FDA 483 OBSERVATION · #146 OF 1,945 MOST-CITED
Batch record - every batch
FDA cited this observation 210 times across 187 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Batch production and control records were not prepared for each batch, or existing records are incomplete — missing the documentation of each significant step, in-process controls, equipment identification, and the accurate reproduction of the master production record required by §211.188.
Why FDA writes it — The batch record is the contemporaneous proof that a specific lot was made correctly. Without a complete record for every batch, FDA cannot confirm the product was manufactured per the approved process, and any deviation, weighing, or control that went unrecorded is unverifiable after the fact.
- Prepare a batch production and control record for every batch by accurately reproducing the approved master production record.
- Document each significant manufacturing step contemporaneously, including in-process control results and equipment/line identification.
- Capture actual quantities, yields, and the identity of personnel performing and checking each critical step.
- Require quality-unit review of the completed batch record as a release gate, with all discrepancies resolved.
- Steps are back-filled at end of shift rather than recorded at the time of performance, leaving gaps.
- The executed record diverges from the master because a process change was not carried into the batch template.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.8× the rate of the average FDA-cited firm (29.4% vs 7.8%), across 187 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
You did not prepare a batch production record every time you manufactured a batch of dietary supplement.
You did not prepare a batch production record every time you manufactured a batch of dietary supplement.
You did not prepare a batch production record every time you manufactured a batch of dietary supplement.
You did not prepare a batch production record every time you manufactured a batch of dietary supplement.
You did not prepare a batch production record every time you manufactured a batch of dietary supplement.
You did not prepare a batch production record every time you manufactured a batch of dietary supplement.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →